SKYRIZI® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis1 Approval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials which include a new 55 mg pre-filled syringe to support...